Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC)

 Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC)

Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC)

Shots:

  • The P-III KEYNOTE-426 Study involves assessing of Keytruda (pembrolizumab, 200mg, IV, q3w) + Inlyta (axitinib, 5mg, PO, bid) vs sunitinib (50 mg, PO, qd@4w) monothx in 861 patients with 1L Advanced RCC
  • P-III KEYNOTE-426 results: Reduction in risk of death 47%, 31% reduction in the risk of progression of disease, ORR (59.3% vs 35.7%), CR (5.8% vs 1.9%), PR (53.5% vs 33.8%), survival rate @12/18 mos. (89.9%, 82.3% vs 78.3%, 72.1%), mPFS (15.1 vs 11.1 mos.), TRAEs (62.9% vs 58.1%), Presented at ASCO GU 2019
  • Keytruda (pembrolizumab) 100mg IV is a mAb, used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2, further activating T lymphocytes. The US FDA has granted PR to its sBLA for 1L advance RCC with its PDUFA date 20 Jun,2019

Click here to read full press release/ article| Ref: Merck | Image: PM Live

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post